Toggle navigation image image
Toggle navigation logologo
image image
  • About Inflarx
    • Leadership Team
    • Board
    • Company History
    • Vision
  • R&D
    • About Complement
    • About C5A
    • Technology
    • Pipeline
    • Clinical Development
      • Hidradenitis Suppurativa
        • Shine Study FAQ
      • ANCA-Associated Vasculitis
      • Pyoderma Gangraenosum
      • COVID-19
      • cSCC
    • Clinical Trials
    • Publications & Posters
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Annual/Extraordinary General Meetings
    • E-mail alerts
  • Career
    • Open Positions
      • Office Manager (m/w/d)
      • Controller (m/w/d)

Pipeline

  • Home
  • R&D
  • Pipeline

Pipeline

   Expand all    Collapse all
The resolution is to low for viewing the pipelines. Please rotate your device or use a desktop computer for viewing the pipelines. (resolution should be larger than 1024 width).
FRANCHISE
INDICATIONS
PRE-CLINICAL
PHASE I
PHASE II
PHASE III
UPDATE

Immuno-dermatology
Pyoderma Gangraenosum (PG)


   Positive Phase IIa open label results

Pyoderma Gangraenosum (PG)

  • InflaRx's lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Pyoderma Gangraenosum (PG), a rare ulcerative skin disorder.
  • InflaRx recently released positive interim results from three cohorts in its’ Phase II clinical study to investigate a potential benefit of vilobelimab for patients suffering from PG. In Q4’21, this study completed its treatment period with the observation period to be completed in the 1H’22.
  • Read more here.
Vilobelimab (IFX-1)
C5a Inhibitor
Life-threatening Inflammatory Diseases
Critical COVID-19


   Phase II results published;
   Phase III encouraging topline data
   released in Q1 2022

 

Critical COVID-19

  • InflaRx's lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including critical COVID-19.
  • The program is being funded by grants from the German Ministry of Research and Education along with the German Ministry of Health.
  • For more information about this trial, please visit www.clinicaltrials.gov or click here.
  • Additional information about COVID-19 and data to date with vilobelimab in this indication can be found here.

Oncology
Cutaneous Squamous Cell Carcinoma (cSCC)


   Phase II trial ongoing

PD-1 or PD-L1 inhibitor Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)

  • InflaRx has entered into a clinical collaboration agreement with Merck & Co, Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) to evaluate the combination of vilobelimab and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with a PD-1 or PD-L1 inhibitor Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC). In June 2021, the first patient was dosed in a Phase IIa clinical study with two vilobelimab arms, including one with KEYTRUDA®.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, U.S.A, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
  • Read more here
IFX002
C5a Inhibitor
Undisclosed Chronic Inflammatory and Autoimmune Diseases


   Developing for optimized use for other
   chronic inflammatory indications

IFX-2

  • IFX-2 is an advancement of vilobelimab technology, in preclinical development. IFX-2 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered pharmacokinetic properties.
  • IFX-2 was developed to target chronic inflammatory diseases with high unmet medical need. Recent scientific publications suggest a fundamental role of the complement factor C5a for various neutrophil driven diseases but also for the disturbance of the T-cell homeostasis, thereby contributing to mechanisms involved in chronic and autoimmune inflammatory diseases. Therapies blocking the C5a / C5aR axis are believed to induce regulatory T-cell generation and decrease Th17- and Th1- type responses. Thus, a therapeutic anti-C5a approach would be applicable within a large variety of T-cell driven inflammatory diseases.
INF904
Oral C5aR Inhibitor
Undisclosed Chronic Inflammatory and Autoimmune Diseases


   First-in-humans study to be initiated in
   H2 2022

IFX-2

Quick Links
  • Impressum
  • Privacy
  • Technology
  • News
  • Career
  • Disclaimer
  • Contact
  • Newsletter
  • Member area
Contact Jena

InflaRx N.V. / InflaRx GmbH
Winzerlaer Str. 2
07745 Jena

+49 3641 508 180

info@inflarx.de

InflaRx on Linkedin

Contact Munich

InflaRx N.V. / InflaRx GmbH
Fraunhoferstraße 22
82152 Martinsried

+49 89 414 189 78 00

info@inflarx.de

Contact Ann Arbor

InflaRx Pharmaceuticals Inc.
600 S. Wagner Rd.
Ann Arbor, MI 48103

info@inflarx.de

© Copyright 2017 All Rights Reserved.
  • Developed by Ementals